Y mAbs Therapeutics Total Assets
Y mAbs Therapeutics total assets. Based on the latest financial reports, Y mAbs Therapeutics (YMAB) holds total assets worth $117.21 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see YMAB market cap for the company's overall valuation and market capitalisation.
Total Assets of Y mAbs Therapeutics (2016–2024)
Total assets of Y mAbs Therapeutics from 2016 to 2024. This chart illustrates how Y mAbs Therapeutics's total assets have evolved over time, based on quarterly financial data. See current stock price of Y mAbs Therapeutics for real-time trading data and today's change.
Y mAbs Therapeutics - Asset Composition Analysis
Y mAbs Therapeutics Total Assets Breakdown (December 2024)
Y mAbs Therapeutics total assets breakdown as of December 2024. Y mAbs Therapeutics's total assets of $117.21 Million consist of 82.2% current assets and 17.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 56.1% |
| Accounts Receivable | $19.69 Million | 16.4% |
| Inventory | $7.21 Million | 6.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.28 Million | 1.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Y mAbs Therapeutics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore YMAB working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Y mAbs Therapeutics's current assets represent 82.2% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 56.1% of total assets in 2024, down from 97.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 16.4% of total assets.
Y mAbs Therapeutics Competitors by Total Assets
Key competitors of Y mAbs Therapeutics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Y mAbs Therapeutics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.00 | 2.92 | 6.74 |
| Quick Ratio | 3.58 | 2.72 | 6.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $68.84 Million | $83.29 Million | $113.43 Million |
Y mAbs Therapeutics - Advanced Valuation Insights
This section examines the relationship between Y mAbs Therapeutics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.47 |
| Latest Market Cap to Assets Ratio | 3.26 |
| Asset Growth Rate (YoY) | -6.2% |
| Total Assets | $119.90 Million |
| Market Capitalization | $391.22 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Y mAbs Therapeutics's assets at a significant premium (3.26x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Y mAbs Therapeutics's assets decreased by 6.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Y mAbs Therapeutics (2016–2024)
The table below shows the annual total assets of Y mAbs Therapeutics from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $119.90 Million | -6.23% |
| 2023-12-31 | $127.87 Million | -9.61% |
| 2022-12-31 | $141.46 Million | -33.52% |
| 2021-12-31 | $212.78 Million | +61.14% |
| 2020-12-31 | $132.05 Million | -38.97% |
| 2019-12-31 | $216.37 Million | +42.42% |
| 2018-12-31 | $151.92 Million | +64.91% |
| 2017-12-31 | $92.13 Million | +433.73% |
| 2016-12-31 | $17.26 Million | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more